Different Variants in Reverse Transcriptase Domain Determined by Ultra-deep Sequencing in Treatment-naive and Treated Indonesian Patients Infected with Hepatitis B Virus.

ABSTRACT: A nucleos(t)ide analog (NA) is the common antiviral drug available for directly treating hepatitis B virus (HBV) infection. However, its application has led to the emergence of NA-resistant mutations mostly in a conserved region of the reverse transcriptase domain of HBV polymerase. Harboring NA-resistant mutations decreases drug effectiveness and increases the frequency of end-stage liver disease. The invention of next-generation sequencing that can generate thousands of sequences from viral complex mixtures provides opportunities to detect minor changes and early viral evolution under drug stress. The present study used ultra-deep sequencing to evaluate discrepant quasispecies in the reverse transcriptase domain of HBV including NA-resistant hotspots between seven treatment-naïve Indones

SUBMITTER: Wasityastuti W 

PROVIDER: S-EPMC5433726 | biostudies-literature | 2016 Jun

REPOSITORIES: biostudies-literature